ramucirumab,pembrolizumab
eli lilly,merck
['lcsm,(-blcsm)', 's1800a', 'lung', 'ramucirumab', '9004']
#asco22 abs#9004 presents #lungmap s1800a ph ii ramucirumab+pembro vs soc in 2nd line #lcsm after progression on io mos 15 vs 11.6 mths, but orr/pfs benefit
encouraging results! 1 st 2nd line io/vegfi trial with os 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows https://t.co/dsiuV460lQ, Views my own